Skip to main content

Table 1 Biochemistry before and during treatment with zoledronic acid and denosumab

From: Clinical improvement in a patient with monostotic melorheostosis after treatment with denosumab: a case report

   Before treatment After treatment
Zoledronic acid
After treatment denosumab Treatment
denosumab
Treatment denosumab
3 Jul 2013 24 Sep 2013 28 Dec 2015 23 Mar 2016 03 Feb 2017
P-Calcium mmol/L 2.27   2.32 2.33 2.49
P-Ionized calcium mmol/L    1.22 1.2 1.23
P-Alkaline phosphatase U/L 58   43 33 42
P-Alkaline phosphatase, bone type U/L   5.6 7.2 6.2 7.1
P-Osteocalcin μg/ L   6.5 9.2 7 5
P-Parathyrin (PTH) pmol/L    5.23 6.15 8.8
P-25-hydroxy-vitamin D nmol/L 207   140   98
CTx pmol/L   < 0.03 < 0.03 < 0.03 < 0.03
PINP μg/L   12 15.6 11 11.4
Plasma (P)
    Jun 2015 to Oct 2015 Oct 2015 to Dec 2015 Feb 2015 to Mar 2016  
Mean VAS score   4 4.3 4.5
Mean VAS (full year)   8 8 6 5 4
% days with pain killers    23 36   0
  1. PTH parathyroid hormone, VAS visual analog scale